Departments of *Urology †Internal Medicine, Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center Yale University, New Haven, CT ‡Department of Radiation Oncology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA §Department of Surgery, Fox Chase Cancer Center-Temple University Health System, Philadelphia, PA ∥Division of Health Care Policy & Research, Knowledge and Evaluation Research Unit ¶Department of Urology, Mayo Clinic, Rochester #Division of Health Care Policy & Research, Mayo Clinic, Rochester, MN **Department of Radiation Oncology, Cancer Outcomes, Public Policy, and Effectiveness Research Center (COPPER), Yale University, New Haven, CT ††Division of Urology, Harvard Medical School, Brigham and Women's Hospital, Boston, MA ‡‡HealthPartners Institute for Education and Research, Minneapolis, MN §§Cancer Prognostics and Health Outcomes, University of Montreal Health Center, Montreal, QC, Canada ∥∥Bioethics Research Unit, Knowledge and Evaluation Research Unit, Division of General Medicine, Mayo Clinic, Rochester, MN.
Med Care. 2014 Jul;52(7):579-85. doi: 10.1097/MLR.0000000000000155.
With the growing concerns about overtreatment in prostate cancer, the extent to which radiation oncologists and urologists perceive active surveillance (AS) as effective and recommend it to patients are unknown.
To assess opinions of radiation oncologists and urologists about their perceptions of AS and treatment recommendations for low-risk prostate cancer.
National survey of specialists.
Radiation oncologists and urologists practicing in the United States.
A total of 1366 respondents were asked whether AS was effective and whether it was underused nationally, whether their patients were interested in AS, and treatment recommendations for low-risk prostate cancer. Pearson's χ test and multivariate logistic regression were used to test for differences in physician perceptions on AS and treatment recommendations.
Overall, 717 (52.5%) of physicians completed the survey with minimal differences between specialties (P=0.92). Although most physicians reported that AS is effective (71.9%) and underused in the United States (80.0%), 71.0% stated that their patients were not interested in AS. For low-risk prostate cancer, more physicians recommended radical prostatectomy (44.9%) or brachytherapy (35.4%); fewer endorsed AS (22.1%). On multivariable analysis, urologists were more likely to recommend surgery [odds ratio (OR): 4.19; P<0.001] and AS (OR: 2.55; P<0.001), but less likely to recommend brachytherapy (OR: 0.13; P<0.001) and external beam radiation therapy (OR: 0.11; P<0.001) compared with radiation oncologists.
Most prostate cancer specialists in the United States believe AS effective and underused for low-risk prostate cancer, yet continue to recommend the primary treatments their specialties deliver.
随着人们对前列腺癌过度治疗的担忧日益增加,放射肿瘤学家和泌尿科医生对主动监测(AS)的有效性的看法以及向患者推荐 AS 的程度尚不清楚。
评估放射肿瘤学家和泌尿科医生对 AS 的看法以及他们对低危前列腺癌的治疗建议。
全国范围内对专家进行的调查。
在美国执业的放射肿瘤学家和泌尿科医生。
共有 1366 名受访者被问及 AS 是否有效,以及 AS 在全国范围内是否未得到充分利用,他们的患者是否对 AS 感兴趣,以及对低危前列腺癌的治疗建议。采用 Pearson χ 检验和多变量逻辑回归检验医生对 AS 和治疗建议的看法差异。
共有 717 名(52.5%)医生完成了调查,不同专业之间差异较小(P=0.92)。尽管大多数医生报告 AS 有效(71.9%)且在美国未得到充分利用(80.0%),但 71.0%的医生表示他们的患者对 AS 不感兴趣。对于低危前列腺癌,更多的医生推荐根治性前列腺切除术(44.9%)或近距离放射治疗(35.4%);较少的医生推荐 AS(22.1%)。多变量分析显示,泌尿科医生更倾向于推荐手术[比值比(OR):4.19;P<0.001]和 AS(OR:2.55;P<0.001),而不太倾向于推荐近距离放射治疗(OR:0.13;P<0.001)和外照射放疗(OR:0.11;P<0.001),而放射肿瘤学家则倾向于推荐这些治疗方法。
美国大多数前列腺癌专家认为 AS 对低危前列腺癌有效且未得到充分利用,但仍继续推荐他们所在专业提供的主要治疗方法。